



維奧醫藥控股有限公司
Vital Pharmaceutical Holdings Limited

(Formerly known as “Vital BioTech Holdings Limited”)
(Formerly known as “維奧生物科技控股有限公司”)
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1164)

ANNOUNCEMENT
UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS

This announcement is made at the request of The Stock Exchange of Hong Kong Limited.

The Board of Directors (the “Board”) of Vital Pharmaceutical Holdings Limited (the “Company”) has noted today’s increases in the price and the trading volume of the shares of the Company and wish to state that we are not aware of any reasons for such increases save as disclosed in the announcement of the Company dated 13 May 2008 in relation to the earthquake that strike Sichuan on 12 May 2008.

The Board also confirm that there are no negotiations or agreements relating to intended acquisitions or realisations which are discloseable under Rule 13.23 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”), neither is the Board aware of any matter discloseable under the general obligation imposed by Rule 13.09 of the Listing Rules, which is or may be of a price-sensitive nature.

Made by the order of the Board of the Company, the directors of which individually and jointly accept responsibility for the accuracy of this statement.

By Order of the Board
Vital Pharmaceutical Holdings Limited
Leung Wai Pong
Company Secretary

Hong Kong, 16 May 2008

As at the date of this announcement, the Board of the Company comprises six executive directors: Mr. Tao Lung, Mr. Huang Jianming, Mr. Shen Songqing, Mr. Liu James Jin, Mr. Xu Xiaofan and Ms. Guo Lin, and three independent non-executive directors: Mr. Lui Tin Nang, Mr. Lee Kwong Yiu and Mr. Chong Cha Hwa.

“Please also refer to the published version of this announcement in China Daily.”